storage stability raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-06 and is reviewed periodically as new material appears.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
== Temperature control and product preparation == Insulated shipping containers, reflective barriers, gel packs, and phase-change materials manage temperature without generating heat or cooling. These are generally classified as passive thermal packaging. Some packages contain separate compartments that create an exothermic or endothermic reaction. These systems can heat or cool a product without an external appliance. Self-heating food packaging is used for some beverages, meals, and field rations. Microwave packages may contain susceptor materials that absorb microwave energy and convert it into heat. Susceptors can improve surface browning or crisping. Other microwave designs regulate steam release, pressure, or heating distribution. Some dispensing packages meter, mix, foam, spray, or activate their contents during use. Examples include dual-component adhesive cartridges, inhalers, spray containers, and packages that combine ingredients immediately before dispensing. Lubricant-impregnated and low-surface-energy coatings have also been studied as methods of improving the emptying of viscous products from containers.
=== Stability === Ab initio calculations show that a graphene sheet is thermodynamically unstable if its size is less than about 20 nm and becomes the most stable fullerene (as within graphite) only for molecules larger than 24,000 atoms.
== Background == Without reliable tests, health care providers rely mainly on empirical treatments, which result in higher antibiotic use, use of multiple other medicines and underdiagnosis. The tests in the EDL are assessed using the REASSURED criteria; real time connectivity, ease of specimen collection, affordable, sensitive, specific, user-friendly, rapid and robust, results availability, equipment, and delivery. It allows treatments to be more precise. The EDL is a priority list of medical tests, which the WHO defines as "one of the six building blocks of a health system". The EDL provides guidance for individual countries, on which medical tests to use and which not to. A Strategic Group of Experts on In Vitro Diagnostics (SAGE IVD) is appointed by the WHO to advise on its development as it is regularly reviewed and expanded. Different countries can adapt it; the Indian Council of Medical Research produced its own version of the EDL in 2019, a year after the first edition.
=== Fellows of ASMS (since 2025) === 2026 Veronica M. Bierbaum, Catherine E. Costello, Kristina Hakansson, Lisa M. Jones, Susan D. Richardson 2025 Erin S. Baker, Catherine C. Fenselau, P. Jane Gale, Susan Weintraub
=== Pharmacodynamics === Epitiostanol binds directly to the androgen receptor (AR) and estrogen receptor (ER), where it acts as an agonist and antagonist, respectively. It is described as potent in its activity as an antiestrogen and comparatively weak as an AAS. In any case, in terms of AAS potency, epitiostanol has been found to have 11 times the anabolic activity and approximately equal androgenic activity relative to that of the reference AAS methyltestosterone. The mechanism of action of epitiostanol in breast cancer is multimodal; it directly suppresses tumor growth through activation of the AR and inhibition of the ER, and, in premenopausal women, it additionally acts as an antigonadotropin and reducing systemic estrogen levels via AR activation and consequent suppression of the hypothalamic-pituitary-gonadal axis. Epitiostanol is unique among AAS in acting as an antagonist of the ER.
Sources: en.wikipedia.org
Individuals with complete androgen insensitivity syndrome (grades 6 and 7 on the Quigley scale) are born with an external female phenotype, without any signs of genital masculinization, despite having a 46,XY karyotype. CAIS is usually recognized at puberty, which may be slightly delayed, but is otherwise normal except for absent menses and diminished or absent secondary terminal hair. Axillary hair (i.e. armpit hair) fails to develop in one third of all cases. The vulva is normal, although the labia and clitoris are sometimes underdeveloped. Vaginal depth varies widely for CAIS, but is typically shorter than normal; one study of eight people with CAIS measured the average vaginal depth to be 5.9 cm (vs. 11.1 ± 1.0 cm for unaffected women ). In some extreme cases, the vagina has been reported to be aplastic (resembling a "dimple"), though the exact incidence of this is unknown. The gonads in people with CAIS are testes; during the embryonic stage of development, testes form in an androgen-independent process that occurs due to the influence of the SRY gene on the Y chromosome. They may be located intra-abdominally, at the internal inguinal ring, or may herniate into the labia majora, often leading to the discovery of the condition. Testes in those affected have been found to be atrophic upon gonadectomy. Testosterone produced by the testes cannot be directly used due to the mutant androgen receptor that characterizes CAIS; instead, it is aromatized into estrogen, which effectively feminizes the body and accounts for the normal female phenotype observed in CAIS.
Oxidative phosphorylation works by using energy-releasing chemical reactions to drive energy-requiring reactions. The two sets of reactions are said to be coupled. This means one cannot occur without the other. The chain of redox reactions driving the flow of electrons through the electron transport chain, from electron donors such as NADH to electron acceptors such as oxygen and hydrogen (protons), is an exergonic process – it releases energy, whereas the synthesis of ATP is an endergonic process, which requires an input of energy. Both the electron transport chain and the ATP synthase are embedded in a membrane, and energy is transferred from the electron transport chain to the ATP synthase by movements of protons across this membrane, in a process called chemiosmosis. A current of protons is driven from the negative N-side of the membrane to the positive P-side through the proton-pumping enzymes of the electron transport chain. The movement of protons creates an electrochemical gradient across the membrane, which is called the proton-motive force. It has two components: a difference in proton concentration (a H+ gradient, ΔpH) and a difference in electric potential, with the N-side having a negative charge. ATP synthase releases this stored energy by completing the circuit and allowing protons to flow down the electrochemical gradient, back to the N-side of the membrane. The electrochemical gradient drives the rotation of part of the enzyme's structure and couples this motion to the synthesis of ATP.
=== January === 1 January Figures show the annual number of migrants crossing the English Channel fell during 2023, doing so for the first time since records began. The provisional annual total for 2023 is 29,437, a 36% decrease from the 2022 total of 45,774. Secretary of State for Defence Grant Shapps says that British forces are ready to act against Houthi rebels targeting cargo ships in the Red Sea. VAT on period pants is abolished, potentially making the products cheaper to buy. A 5% increase in the price cap on domestic energy comes into force for England, Scotland and Wales. Kimberlee Singler, a 35-year-old mother accused of the murder of two of her children in Colorado, United States, appears before Westminster Magistrates Court for extradition proceedings following her arrest in London on 30 December 2023. HMRC announces a crackdown on tax evasion by those who make extra cash from "side hustle" websites like Airbnb, Amazon, eBay and Etsy. 2 January Storm Henk: The Met Office issues a severe weather warning as Storm Henk hits parts of the UK, bringing winds of up to 80 mph (128 km/h), along with the risk of flooding. A man in his 50s dies on the A433 near Kemble, Gloucestershire after a tree falls on his car during high winds. At the London Eye, strong winds blow open a pod hatch while a family of 11 is 400 ft in the air. Footage emerges of a mother and her three-year-old daughter being rescued from a submerged car in Birmingham. An 87-year-old woman dies on the B4526 near Crays Pond, Oxfordshire after the car she is driving hits a fallen tree.
DAD discovered in Gram-negative E. coli B membrane can convert L-amino acids into D-amino acids as well. Additionally, D-amino acid dehydrogenase is used in dye-linked dehydrogenase (dye-DHs) which uses artificial dyes such as 2,6-dichloroindophenol (DCIP) as their electron acceptor rather than using their natural electron acceptors. This can accelerate the reaction between the enzyme and the substrate when the electrons are being transferred.
In May 2024, Cerebras in collaboration with researchers from Sandia National Laboratories, Lawrence Livermore National Laboratory, Los Alamos National Laboratory, and the National Nuclear Security Administration, simulated 800,000 atoms interacting with each other, calculating the interactions in increments of one femtosecond at a time. Each step took just microseconds to compute on the Cerebras WSE-2, much faster than on the Frontier supercomputer. Cerebras was named to the "100 Most Influential Companies list" by Time in May 2024. In June 2024, Cerebras announced a collaboration with Dell Technologies, for AI compute infrastructure for generative AI. In August 2024, Cerebras launched its AI inference service, which it claimed to be ten to twenty times faster than systems built using Nvidia's H100 Hopper graphics processing units. In January 2025, the Mayo Clinic announced a collaboration with Cerebras to combine genomic data with de-identified data from patient records and medical evidence to explore the ability to predict a patient's response to treatments to manage disease. In January 2025, Cerebras announced support for DeepSeek's R1 70B reasoning model at 1,600 tokens/second. In February 2025, Mistral AI began using Cerebras products to power its Le Chat service and reached a speed record. Also in February 2025, Cerebras announced a partnership with Perplexity AI's Sonar model, which runs on Cerebras chips at 1,200 tokens per second.
Sources: en.wikipedia.org
glycogen A branched polysaccharide composed of as many as 30,000 covalently bonded units of the monosaccharide glucose which functions as the primary form of short-term energy storage in most animal cells. Glycogen reserves are especially abundant in muscle and liver cells, where they can be metabolized at-need into their component glucoses as a means of buffering blood sugar levels, a process known as glycogenolysis.
Formation of these secondary structures efficiently satisfies the hydrogen bonding capacities of the peptide bonds. The secondary structures can be tightly packed in the protein core in a hydrophobic environment, but they can also be present at a polar protein surface. Each amino acid side chain has a limited volume to occupy and a limited number of possible interactions with other nearby side chains, a situation that must be taken into account in molecular modeling and alignments.
Bryant Park contains a Beaux-Arts granite restroom structure on the northern border, along 42nd Street. There are two facilities, one for men and women, both of which are 315 square feet (29.3 m2). These were built in 1911 along with the NYPL Main Branch, but due to the park's landmark status, they cannot be expanded. The exterior of each building contains a frieze with garland motifs. After being closed in the mid-1960s, they were restored by Kupiec & Koutsomitis and reopened in 1992. The restrooms have been described as being among the city's best. A subsequent renovation in 2006 solidified their status as, in the words of then-New York City Parks Commissioner Adrian Benepe, "the gold standard for park comfort stations." The restrooms were renovated again in 2017. Following the 2017 renovation, the restrooms contained rotating artworks selected from a collection of 225 works, as well as fresh flowers, classical music, attendants, and automatic toilets and faucets.
=== Bead method === A common laboratory-scale mechanical method for cell disruption uses glass, ceramic, or steel beads, 0.1–2 mm (0.004–0.08 in) in diameter, mixed with a sample suspended in an aqueous solution. First developed by Tim Hopkins in the late 1970s, the sample and bead mix is subjected to high level agitation by stirring or shaking. Beads collide with the cellular sample, cracking open the cell to release the intracellular components. Unlike some other methods, mechanical shear is moderate during homogenization resulting in excellent membrane or subcellular preparations. The method, often called "bead beating", works well for all types of cellular material - from spores to animal and plant tissues. It is the most widely used method of yeast lysis, and can yield breakage of well over 50% (up to 95%). It has the advantage over other mechanical cell disruption methods of being able to disrupt very small sample sizes, process many samples at a time with no cross-contamination concerns, and does not release potentially harmful aerosols in the process. In the simplest example of the method, an equal volume of beads are added to a cell or tissue suspension in a test tube and the sample is vigorously mixed on a common laboratory vortex mixer. While processing times are slow, taking 3–10 times longer than that in specialty shaking machines, it works well for easily disrupted cells and is inexpensive.
=== Endogenous role === DMT exists naturally in humans and other animals; it may play significant roles in mammalian physiology—potentially as a neurotransmitter, hormone, and immunomodulator—despite longstanding skepticism based on outdated or flawed evidence.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.